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Background
Enhancing throughput of bioprocess development has
become increasingly important to rapidly screen and
optimize cell culture process parameters. With increas-
ing timeline pressures to get therapeutic candidates into
the clinic, resource intensive approaches such as the use
of shake flasks and bench-top bioreactors may limit the
design space for experimentation to yield highly produc-
tive processes. The need to conduct large numbers of
experiments has resulted in the use of miniaturized
high-throughput (HT) technology for bioprocess devel-
opment. One such high-throughput system is the
ambr™ platform, a robotically driven, mini-bioreactor
system developed by TAP-Sartorius.
In this study we assessed and compared the perfor-
mance parameters of ambr™ mini-bioreactor runs to 2L
glasses , 80L and 400L stainless steel bioreactors using a
CHO cell line producing a recombinant monoclonal
antibody. The daily parameters monitored during the
cultures were cell growth and cell viability, offline pH
and dissolved oxygen, metabolite profiles (glucose, lac-
tate and ammonia) and monoclonal antibody titer. In
addition, we compared the product quality attributes
(high and low molecular weight species, charge variants)
of the clarified cell culture fluid post Protein-A elution
generated in the mini-bioreactor run to the larger man-
ufacturing scales.
Materials and methods
A genetically engineered Dihydrofolate Reductase
(DHFR)-/ - DG44 Chinese Hamster Ovary (CHO) cell
line with Methotrexate (MTX) as a selective agent,
expressing a recombinant monoclonal antibody was
used. Cells were cultivated for 14 days in a fed-batch
mode in a chemically defined medium and fed according
to process description.
Culture systems: Different bioreactor scales were used
in this study : ambr™48 (TAP -Sartorius Biosystems),
an automated system with 48 disposable microbioreac-
tor vessels, 2L stirred tank glasses bioreactors with Bio-
stat B-DCUII control systems (Sartorius Stedim), 80L
and 400L stainless-steel bioreactors (Zeta).
Data was analysed using JMP statistical (SAS)
program.
All the experiments were conducted using the same
cell bank at the same cell age at bioreactor inoculation.
pH (7.0 +/- 0.2) was controlled using CO2 and base
addition.
The scale independent factors (pH, DO set point,
seeding density, temperature, culture duration, media
and feed composition), were the same for all the scales.
The scale dependent factors (culture start volume,
feed volumes) were linearly adapted. Agitation speed
and aeration that were determined theoretically or
though experiment.
Sampling plans and sample volumes were especially
adapted to the ambr™ system to take into account the
low bioreactor volume.* Correspondence: frederic.delouvroy@ucb.com
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A miniaturised metabolite assay was developed to
allow daily measurements glucose, ammonium, lactate
and osmolality using low analyte volumes.
Viable Cell Density (VCD) and cell viability were mea-
sured using a ViCell® XR cell counter (Beckman Coulter)
directly connected to the ambr™ system. Metabolites
(glucose, lactate, ammonium) concentrations were mea-
sured by an enzymatic assay using a UV-method (R-Bio-
pharm) for the ambr™ vessels and by a BioProfile
Analyser 400 (Nova Biomedical) for larger scale bioreac-
tors. For all the systems, pH measurement was obtained
with a BioProfile pHOx pH/Gas Analyser (Nova Biome-
dical). And osmolality was obtained using a Osmometer
(Advanced Instruments). Production titers were mea-
sured throughout the culture using an Octet QK (Forte-
Bio) and after 14 days with protein A HPLC (Waters).
Product quality attributes (PQA) of the produced
monoclonal antibodies were analysed as follows: Cell
culture fluid samples were centrifuged and filtered to
remove cell debris. The monoclonal antibodies were
purified by ÄKTA-express (GE Healthcare) Protein-A
purification. The neutralized eluate was used for product
quality analysis. Charge variant analysis determined the
relative percentage of acidic, basic and main isoform
species of the mAb by means of an imaged capillary
isoelectric focusing system (Protein Simple, iCE3) after a
Carboxypeptidase B digestion. Size exclusion analysis
method determined the percentage of aggregates, mono-
mers and fragment levels by size exclusion chromatogra-
phy (SE-UPLC).
Results and discussion
To assess the capabilities of the ambr™ system to
mimic traditional larger scale stirred tank bioreactors in
terms of process performance, the 19 mini-bioreactors
have been compared to 2L (n = 6), 80L (n = 3) and
400L (n = 3) bioreactors (Table 1).
Good reproducibility was obtained amongst the repli-
cates intra-runs. Inter-runs, the different ambr™ bior-
eactor batches showed similar trends for cell viability.
Nevertheless, a higher variability was observed for the
VCD and the mAb titer. This might be due to the biolo-
gical variability of the process. Although variability was
observed, cells showed comparable mAb specific pro-
ductivity between the different ambr™ batches. In terms
of pH, and metabolite comparable profiles were
obtained within the different mini-bioreactors ambr™
runs.
Compare to larger scales (2L glasses, 80L and 400L stain-
less steel stirred tank bioreactors), cell growth, product
titer, pH, and metabolites in ambr™ mini-bioreactors dis-
played similar profiles to larger scales (Figure 1).
The product quality analysis showed comparable
results between ambr™ and larger scale bioreactors
(Figure not showed).
This study showed that for this antibody, ambr™ could
successfully mimic larger scale bioreactors and give good
predictive results. The equipment can be used as a high
throughput platform for cell culture development.
Table 1. Number of bioreactors and batches performed
at different scales





Figure 1 Comparison between the different scales. A: Viable cell density and viability profiles. B: mAb titer profile. C: mAb titer and average
Qp value at day14. D: Osmolality and glucose profiles. E: Lactate and ammonium profiles. F: Offline pH profiles
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However, the scale down model developed in the mini-
bioreactors might require fine tuning for each new biolo-
gic producing cell line.
The comparability in terms of process performance
and product quality attribute between the 15mL ambr™
mini-bioreactors and the 400L stainless steel production
bioreactors enables lean, fast and efficient process devel-
opment minimising time to clinic.
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